ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Top radiology experts, researchers, innovators and healthcare professionals gathered in Dubai today for the 13th Pan-Arab ...

Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, today presented positive preclinical data demonstrating the satisfactory ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Mpox and Smallpox Threats: Vaccine Development and Biosecurity Policy ...

Building upon significant strides in the capacity and coverage of the National Blood Transfusion Service (NBTS), Eritrea has taken a crucial step to fortify blood safety with the official launch of ...

In influenza vaccination, PFSs may cost more per dose than multidose vials (MDVs), but could offer advantages in speed, disposal, wastage and patient safety owing to premeasured accurate doses ...

An independent vaccine advisory committee to the Centers for Disease Control and Prevention met to discuss and vote on ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

With a focus on endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) and thoracoabdominal aortic aneurysms ( ...